| Active substance | pemigatinib |
| Holder | Incyte Corporation |
| Status | closed |
| Indication | adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy |
| Public documents | Approbation |
| Last update | 11/08/2022 |